Nurix Therapeutics (NRIX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

NRIX · Stock Price

USD 16.28+6.78 (+71.37%)

Market Cap: $1.7B

Historical price data

Market Cap: $1.7BPipeline: 8 drugsPatents: 14Founded: 2009Employees: 201-500HQ: Brisbane, United States

Sector Ranking#151 in Small Molecule Drugs #32 in Oncology (General)

Overview

Nurix Therapeutics is a leader in the targeted protein degradation (TPD) space, with a mission to develop breakthrough therapies for cancer and autoimmune diseases by harnessing the body's natural protein disposal systems. The company's core achievement is the development of its integrated DELigase™ discovery platform, which combines DNA-encoded libraries (DEL), artificial intelligence (AI), and deep E3 ligase expertise to rapidly generate novel degrader candidates. Its strategy involves advancing a multi-modal pipeline of oral degraders and antibody-conjugated degraders (DACs), with its lead asset, bexobrutideg (NX-5948), in Phase 2 trials for hematologic cancers. Nurix aims to establish degrader-based medicines as a cornerstone of future patient care through both internal development and strategic partnerships.

OncologyAutoimmune Diseases

Technology Platform

The DELigase™ platform integrates DNA-encoded library (DEL) screening, artificial intelligence (AI), and deep E3 ligase expertise to discover and optimize novel targeted protein degraders and Degrader-Antibody Conjugates (DACs).

Pipeline

8

8 drugs in pipeline

Drug	Indication	Stage
NX-5948	Chronic Lymphocytic Leukemia (CLL)	Phase 2
NX-5948	Chronic Lymphocytic Leukemia (CLL)	Phase 1
NX-2127	Chronic Lymphocytic Leukemia (CLL)	Phase 1
NX-5948	Healthy Volunteer	Phase 1
NX-5948 + Esomeprazole	Healthy Volunteer	Phase 1

Funding History

4

Total raised:$373M

IPO$175MUndisclosedJul 23, 2020

Series C$120MEcoR1 CapitalJan 15, 2020

Series B$55MForesite CapitalJun 15, 2018

Series A$23MThird Rock VenturesJan 15, 2014

Opportunities

Nurix's lead BTK degrader, bexobrutideg, addresses a multi-billion-dollar market with a potential best-in-class profile for overcoming resistance in B-cell cancers.

Its pioneering DAC platform and immunology pipeline open significant new markets in solid tumors and autoimmune diseases, representing substantial long-term growth vectors.

Risk Factors

The company faces significant clinical development risk, as all programs are in early stages, and intense competition in the targeted protein degradation field.

As a pre-revenue company, it remains dependent on capital markets and partnership milestones to fund operations.

Competitive Landscape

Nurix competes with other TPD-focused biotechs (e.g., Arvinas, Kymera) and large pharma, differentiating itself through its integrated DELigase discovery engine and dual modality approach (oral degraders and DACs). Its strategic partnerships with GSK and Sanofi provide validation and resources.